Search

Your search keyword '"Stich, Maximilian"' showing total 23 results
Start Over Author "Stich, Maximilian"
23 results on '"Stich, Maximilian"'

1. Humoral immune response and live-virus neutralization of the SARS-CoV-2 omicron (BA.1) variant after COVID-19 mRNA vaccination in children and young adults with chronic kidney disease

Author

Stich, Maximilian, Di Cristanziano, Veronica, Tönshoff, Burkhard, Weber, Lutz Thorsten, Dötsch, Jörg, Rammer, Marian Theodor, and Rieger, Susanne

Subjects
Children -- Diseases, Chronic kidney failure -- Care and treatment -- Patient outcomes, Immune response -- Analysis, Health
Abstract

Background Data on humoral immune response to standard COVID-19 vaccination are scarce in adolescent patients and lacking for children below 12 years of age with chronic kidney disease including kidney transplant recipients. Methods We therefore investigated in this retrospective two-center study (DRKS00024668; registered 23.03.2021) the humoral immune response to a standard two-dose mRNA vaccine regimen in 123 CKD patients aged 5-30 years. A live-virus assay was used to assess the serum neutralizing activity against the SARS-CoV-2 omicron (BA.1) variant. Results Children aged 5-11 years had a comparable rate and degree of immune response to adolescents despite lower vaccine doses (10 [micro]g vs. 30 [micro]g BNT162b2). Treatment with two (odds ratio 9.24) or three or more (odds ratio 17.07) immunosuppressants was an independent risk factor for nonresponse. The immune response differed significantly among three patient cohorts: 48 of 77 (62.3%) kidney transplant recipients, 21 of 26 (80.8%) patients on immunosuppressive therapy, and 19 of 20 (95.0%) patients with chronic kidney disease without immunosuppressive therapy responded. In the kidney transplant recipients, immunosuppressive regimens comprising mycophenolate mofetil, an eGFR of 1411 BAU/mL, respectively, showed a neutralization activity against the omicron variant. Conclusion A standard mRNA vaccine regimen in immunosuppressed children and adolescents with kidney disease elicits an attenuated humoral immune response with effective live virus neutralization against the omicron variant in approximately 10% of the patients, underlying the need for omicron-adapted vaccination. Graphical abstract, Author(s): Maximilian Stich [sup.1] , Veronica Di Cristanziano [sup.2] , Burkhard Tönshoff [sup.1] , Lutz Thorsten Weber [sup.3] , Jörg Dötsch [sup.3] , Marian Theodor Rammer [sup.3] , Susanne Rieger [...]

Published
2023
Full Text
View/download PDF

2. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients

Author

Benning, Louise, Morath, Christian, Bartenschlager, Marie, Kim, Heeyoung, Reineke, Marvin, Beimler, Jörg, Buylaert, Mirabel, Nusshag, Christian, Kälble, Florian, Reichel, Paula, Töllner, Maximilian, Schaier, Matthias, Klein, Katrin, Benes, Vladimir, Rausch, Tobias, Rieger, Susanne, Stich, Maximilian, Tönshoff, Burkhard, Weidner, Niklas, Schnitzler, Paul, Zeier, Martin, Süsal, Caner, Hien Tran, Thuong, Bartenschlager, Ralf, and Speer, Claudius

Published
2022
Full Text
View/download PDF

3. Robust and durable serological response following pediatric SARS-CoV-2 infection

Author

Renk, Hanna, Dulovic, Alex, Seidel, Alina, Becker, Matthias, Fabricius, Dorit, Zernickel, Maria, Junker, Daniel, Groß, Rüdiger, Müller, Janis, Hilger, Alexander, Bode, Sebastian F. N., Fritsch, Linus, Frieh, Pauline, Haddad, Anneke, Görne, Tessa, Remppis, Jonathan, Ganzemueller, Tina, Dietz, Andrea, Huzly, Daniela, Hengel, Hartmut, Kaier, Klaus, Weber, Susanne, Jacobsen, Eva-Maria, Kaiser, Philipp D., Traenkle, Bjoern, Rothbauer, Ulrich, Stich, Maximilian, Tönshoff, Burkhard, Hoffmann, Georg F., Müller, Barbara, Ludwig, Carolin, Jahrsdörfer, Bernd, Schrezenmeier, Hubert, Peter, Andreas, Hörber, Sebastian, Iftner, Thomas, Münch, Jan, Stamminger, Thomas, Groß, Hans-Jürgen, Wolkewitz, Martin, Engel, Corinna, Liu, Weimin, Rizzi, Marta, Hahn, Beatrice H., Henneke, Philipp, Franz, Axel R., Debatin, Klaus-Michael, Schneiderhan-Marra, Nicole, Janda, Ales, and Elling, Roland

Published
2022
Full Text
View/download PDF

4. Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in Households with Children, Southwest Germany, May-August 2020

Author

Stich, Maximilian, Elling, Roland, Renk, Hanna, Janda, Ales, Garbade, Sven F., Muller, Barbara, Krausslich, Hans-Georg, Fabricius, Dorit, Zernickel, Maria, Meissner, Peter, Huzly, Daniela, Grulich-Henn, Jurgen, Haddad, Anneke, Gorne, Tessa, Spielberger, Benedikt, Fritsch, Linus, Nieters, Alexandra, Hengel, Hartmut, Dietz, Andrea N., Stamminger, Thomas, Ganzenmueller, Tina, Ruetalo, Natalia, Peter, Andreas, Remppis, Jonathan, Iftner, Thomas, Jeltsch, Kathrin, Waterboer, Tim, Franz, Axel R., Hoffmann, Georg Friedrich, Engel, Corinna, Debatin, Klaus- Michael, Tonshoff, Burkhard, and Henneke, Philipp

Subjects
Epidemics -- Statistics -- Risk factors -- Germany, Households -- Statistics -- Health aspects, Disease transmission -- Statistics -- Risk factors, Communicable diseases in children -- Statistics -- Risk factors, Pediatric research, Health
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread globally since its emergence in December 2019. As of March 2021, >120 million infections have been reported, and >2.7 million [...]

Published
2021
Full Text
View/download PDF

5. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Author

Varma, Ankur, Biritxinaga, Laura, Saliba, Rima M, Stich, Maximilian, Jauch, Sarah Francesca, Afrough, Aimaz, Honhar, Medhavi, Popat, Uday R, Shafi, Mehnaz A, Shah, Nina, Bashir, Qaiser, Dinh, Yvonne, Hosing, Chitra, Champlin, Richard E, and Qazilbash, Muzaffar H

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Immunology, Regenerative Medicine, Cancer, Orphan Drug, Liver Disease, Infectious Diseases, Hematology, Transplantation, Digestive Diseases, Rare Diseases, Hepatitis - B, Clinical Research, Chronic Liver Disease and Cirrhosis, Hepatitis, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Infection, Good Health and Well Being, Adult, Aged, Case-Control Studies, Female, Hematopoietic Stem Cell Transplantation, Hepatitis B Antibodies, Humans, Incidence, Male, Middle Aged, Multiple Myeloma, Retrospective Studies, Survival Analysis, Transplantation, Autologous, Virus Activation, Multiple myeloma, Reactivation, Resolved HBV infection, Reverse seroconversion, Cardiovascular medicine and haematology
Abstract

Hepatitis B core antibody (HBcAb) seropositivity has been associated with a higher rate of hepatitis B virus (HBV) reactivation after chemotherapy, even in patients who are hepatitis B surface antigen (HBsAg) negative. However, little is known about the risk of HBV reactivation after autologous hematopoietic stem cell transplantation (auto-HCT). We evaluated the incidence of HBV reactivation, liver toxicity, and survival in patients with multiple myeloma (MM) who received auto-HCT at our institution. We retrospectively identified 107 MM patients with resolved HBV infection (HBcAb positive, HBsAg negative) and 125 patients with negative HBV serology (control subjects) who were matched for age, timing of auto-HCT from diagnosis, cytogenetics, disease status at transplant, induction therapy, and preparative regimen. All patients underwent auto-HCT between 1991 and 2013. Primary endpoints were HBV reactivation, defined as HBsAg positivity or ≥10-fold increase in HBV DNA, and hepatotoxicity, as defined in the U.S. National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. In the resolved HBV infection group, 52 patients (49%) were HBsAb positive and 24 (22%) had detectable HBV DNA before auto-HCT. Only 1 patient with resolved HBV infection received pre-emptive antiviral therapy with lamivudine, whereas 4 patients received lamivudine (n = 3) or tenofovir (n = 1) at reactivation after auto-HCT for a median duration of 12 months. HBV reactivation occurred in 7 of 107 patients (6.5%) in the resolved HBV group. Median time to HBV reactivation from auto-HCT was 16 months. The cumulative incidence of grade 2 or greater hepatotoxicity was 30% in the resolved HBV infection group and 22% in the control group (hazard ratio, 1.3; 95% confidence interval, .7 to 2.3; P = .4). Nonrelapse mortality for the 2 groups was not statistically different at 2 years (P = .06), although it trended higher in the control group than in the resolved HBV infection group (8% versus 1%). The median progression-free survival (PFS) and overall survival (OS) durations in the resolved HBV infection and control groups were 21 versus 18 months (P = .5) and 53 versus 67 months (P = .2), respectively. Our data suggest that resolved HBV infection in patients undergoing auto-HCT for MM is associated with a low risk of HBV reactivation and hepatotoxicity; these complications were reversible and did not adversely affect the PFS or OS.

Published
2017

6. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation

Author

Bock, Fabian, Lu, Gary, Srour, Samer A., Gaballa, Sameh, Lin, Heather Y., Baladandayuthapani, Veerabhadran, Honhar, Medhavi, Stich, Maximilian, Shah, Nina Das, Bashir, Qaiser, Patel, Krina, Popat, Uday, Hosing, Chitra, Korbling, Martin, Delgado, Ruby, Rondon, Gabriela, Shah, Jatin J., Thomas, Sheeba K., Manasanch, Elisabet E., Isermann, Berend, Orlowski, Robert Z., Champlin, Richard E., and Qazilbash, Muzaffar H.

Published
2016
Full Text
View/download PDF

7. Live‐virus neutralization of the omicron variant in children and adults 14 months after SARS‐CoV‐2 wild‐type infection

Author

Stich, Maximilian, primary, Benning, Louise, additional, Speer, Claudius, additional, Garbade, Sven F., additional, Bartenschlager, Marie, additional, Kim, Heeyoung, additional, Jeltsch, Kathrin, additional, Tabatabai, Julia, additional, Niesert, Moritz, additional, Janda, Aleš, additional, Renk, Hanna, additional, Elling, Roland, additional, Hoffmann, Georg Friedrich, additional, Kräusslich, Hans‐Georg, additional, Müller, Barbara, additional, Bartenschlager, Ralf, additional, and Tönshoff, Burkhard, additional

Published
2023
Full Text
View/download PDF

8. Longitudinal Analysis of Humoral and Cellular Immunity in SARS-CoV-2 Exposed Families

Author

Dulovic, Alex, primary, Rabsteyn, Armin, additional, Remppis, Jonathan, additional, Engel, Corinna, additional, Gentzcke, Irene K. E., additional, Mueller, Julia, additional, Tuecks, Nadja, additional, Becker, Matthias, additional, Junker, Daniel, additional, Kaiser, Philipp D., additional, Traenkle, Bjoern, additional, Rothbauer, Ulrich, additional, Walz, Juliane Sarah, additional, Peter, Andreas, additional, Hörber, Sebastian, additional, Ganzenmueller, Tina, additional, Iftner, Thomas, additional, Stich, Maximilian, additional, Toenshoff, Burkhard, additional, Henneke, Philipp, additional, Elling, Roland, additional, Debatin, Klaus-Michael, additional, Janda, Aleš, additional, Schneiderhan-Marra, Nicole, additional, Franz, Axel, additional, Lang, Peter, additional, and Renk, Hanna, additional

Published
2023
Full Text
View/download PDF

9. Humoral immune response and live-virus neutralization of the SARS-CoV-2 omicron (BA.1) variant after COVID-19 mRNA vaccination in children and young adults with chronic kidney disease

Author

Stich, Maximilian, primary, Di Cristanziano, Veronica, additional, Tönshoff, Burkhard, additional, Weber, Lutz Thorsten, additional, Dötsch, Jörg, additional, Rammer, Marian Theodor, additional, Rieger, Susanne, additional, Heger, Eva, additional, Garbade, Sven F., additional, Burgmaier, Kathrin, additional, Benning, Louise, additional, Speer, Claudius, additional, Habbig, Sandra, additional, and Haumann, Sophie, additional

Published
2022
Full Text
View/download PDF

10. Waning Immunity 14 Months After SARS-CoV-2 Infection

Author

Stich, Maximilian, primary, Benning, Louise, additional, Speer, Claudius, additional, Garbade, Sven F., additional, Bartenschlager, Marie, additional, Kim, Heeyoung, additional, Gleich, Florian, additional, Jeltsch, Kathrin, additional, Haase, Bettina, additional, Janda, Aleš, additional, Renk, Hanna, additional, Elling, Roland, additional, Schnitzler, Paul, additional, Waterboer, Tim, additional, Hoffmann, Georg Friedrich, additional, Kräusslich, Hans-Georg, additional, Müller, Barbara, additional, Bartenschlager, Ralf, additional, and Tönshoff, Burkhard, additional

Published
2022
Full Text
View/download PDF

11. Long COVID symptoms in exposed and infected children, adolescents and their parents one year after SARS-CoV-2 infection: A prospective observational cohort study

Author

Haddad, Anneke, primary, Janda, Aleš, additional, Renk, Hanna, additional, Stich, Maximilian, additional, Frieh, Pauline, additional, Kaier, Klaus, additional, Lohrmann, Florens, additional, Nieters, Alexandra, additional, Willems, Anna, additional, Huzly, Daniela, additional, Dulovic, Alex, additional, Schneiderhan-Marra, Nicole, additional, Jacobsen, Eva-Maria, additional, Fabricius, Dorit, additional, Zernickel, Maria, additional, Stamminger, Thomas, additional, Bode, Sebastian F.N., additional, Himpel, Theda, additional, Remppis, Jonathan, additional, Engel, Corinna, additional, Peter, Andreas, additional, Ganzenmueller, Tina, additional, Hoffmann, Georg Friedrich, additional, Haase, Bettina, additional, Kräusslich, Hans-Georg, additional, Müller, Barbara, additional, Franz, Axel R., additional, Debatin, Klaus-Michael, additional, Tönshoff, Burkhard, additional, Henneke, Philipp, additional, and Elling, Roland, additional

Published
2022
Full Text
View/download PDF

12. Pulmonary Function and Persistent Clinical Symptoms in Children and Their Parents 12 Months After Mild SARS-CoV-2 Infection

Author

Bode, Sebastian F. N., primary, Haendly, Marisa, additional, Fabricius, Dorit, additional, Mayer, Benjamin, additional, Zernickel, Maria, additional, Haddad, Anneke Donne Maree, additional, Frieh, Pauline, additional, Elling, Roland, additional, Renk, Hanna, additional, Stich, Maximilian, additional, Jacobsen, Eva-Maria, additional, Debatin, Klaus-Michael, additional, and Janda, Ales, additional

Published
2022
Full Text
View/download PDF

13. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients

Author

Süsal, Caner (ORCID 0000-0003-2521-8201 & YÖK ID 351800), Benning, Louise; Morath, Christian; Bartenschlager, Marie; Kim, Heeyoung; Reineke, Marvin; Beimler, Jorg; Buylaert, Mirabel; Nusshag, Christian; Kaelble, Florian; Reichel, Paula; Toellner, Maximilian; Schaier, Matthias; Klein, Katrin; Benes, Vladimir; Rausch, Tobias; Rieger, Susanne; Stich, Maximilian; Toenshoff, Burkhard; Weidner, Niklas; Schnitzler, Paul; Zeier, Martin; Tran, Thuong Hien; Bartenschlager, Ralf; Speer, Claudius, Koç University Hospital, School of Medicine, Süsal, Caner (ORCID 0000-0003-2521-8201 & YÖK ID 351800), Benning, Louise; Morath, Christian; Bartenschlager, Marie; Kim, Heeyoung; Reineke, Marvin; Beimler, Jorg; Buylaert, Mirabel; Nusshag, Christian; Kaelble, Florian; Reichel, Paula; Toellner, Maximilian; Schaier, Matthias; Klein, Katrin; Benes, Vladimir; Rausch, Tobias; Rieger, Susanne; Stich, Maximilian; Toenshoff, Burkhard; Weidner, Niklas; Schnitzler, Paul; Zeier, Martin; Tran, Thuong Hien; Bartenschlager, Ralf; Speer, Claudius, Koç University Hospital, and School of Medicine

Abstract

Seroconversion after COVID-19 vaccination is impaired in kidney transplant recipients. Emerging variants of concern such as the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants pose an increasing threat to these patients. In this observational cohort study, we measured anti-S1 IgG, surrogate neutralizing, and anti-receptor-binding domain antibodies three weeks after a third mRNA vaccine dose in 49 kidney transplant recipients and compared results to 25 age-matched healthy controls. In addition, vaccine-induced neutralization of SARS-CoV-2 wild-type, the B.1.617.2 (delta), and the B.1.1.529 (omicron) variants was assessed using a live-virus assay. After a third vaccine dose, anti-S1 IgG, surrogate neutralizing, and anti-receptor-binding domain antibodies were significantly lower in kidney transplant recipients compared to healthy controls. Only 29/49 (59%) sera of kidney transplant recipients contained neutralizing antibodies against the SARS-CoV-2 wild-type or the B.1.617.2 (delta) variant and neutralization titers were significantly reduced compared to healthy controls (p < 0.001). Vaccine-induced cross-neutralization of the B.1.1.529 (omicron) variants was detectable in 15/35 (43%) kidney transplant recipients with seropositivity for anti-S1 IgG, surrogate neutralizing, and/or anti-RBD antibodies. Neutralization of the B.1.1.529 (omicron) variants was significantly reduced compared to neutralization of SARS-CoV-2 wild-type or the B.1.617.2 (delta) variant for both, kidney transplant recipients and healthy controls (p < .001 for all)., Dietmar Hopp Stiftung; Heidelberg Faculty of Medicine Rahel Goitein-Straus Program; Heidelberg Faculty of Medicine Physician Scientist Program; German Federal Research Network Applied Surveillance and Testing (BFAST); Network University Medicine; Helmholtz Association Initiative and Networking Fund Project Virological and Immunological Determinants of COVID-19 Pathogenesis

Published
2022

14. Role of ABO Blood Group in SARS-CoV-2 Infection in Households

Author

Janda, Ales, primary, Engel, Corinna, additional, Remppis, Jonathan, additional, Enkel, Sigrid, additional, Peter, Andreas, additional, Hörber, Sebastian, additional, Ganzenmueller, Tina, additional, Schober, Sarah, additional, Weinstock, Christof, additional, Jacobsen, Eva-Maria, additional, Fabricius, Dorit, additional, Zernickel, Maria, additional, Stamminger, Thomas, additional, Dietz, Andrea, additional, Groß, Hans-Jürgen, additional, Bode, Sebastian F. N., additional, Haddad, Anneke D. M., additional, Elling, Roland, additional, Stich, Maximilian, additional, Tönshoff, Burkhard, additional, Henneke, Philipp, additional, Debatin, Klaus-Michael, additional, Franz, Axel R., additional, and Renk, Hanna, additional

Published
2022
Full Text
View/download PDF

15. High antibody and reduced cellular response in children up to one year after SARS-CoV-2 infection

Author

Jacobsen, Eva-Maria, primary, Fabricius, Dorit, additional, Class, Magdalena, additional, Topfstedt, Fernando, additional, Lorenzetti, Raquel, additional, Janowska, Iga, additional, Schmidt, Franziska, additional, Staniek, Julian, additional, Zernickel, Maria, additional, Stamminger, Thomas, additional, Dietz, Andrea, additional, Zellmer, Angela, additional, Hecht, Manuel, additional, Rauch, Peter, additional, Blum, Carmen, additional, Ludwig, Carolin, additional, Jahrsdörfer, Bernd, additional, Schrezenmeier, Hubert, additional, Heeg, Maximilian, additional, Mayer, Benjamin, additional, Seidel, Alina, additional, Groß, Rüdiger, additional, Münch, Jan, additional, Bode, Sebastian, additional, Strauss, Gudrun, additional, Renk, Hanna, additional, Elling, Roland, additional, Stich, Maximilian, additional, Voll, Reinhard, additional, Tönshoff, Burkhard, additional, Franz, Axel, additional, Henneke, Philipp, additional, Debatin, Klaus-Michael, additional, Rizzi, Marta, additional, and Janda, Aleš, additional

Published
2022
Full Text
View/download PDF

16. Long COVID Symptoms in a Prospective Cohort of Exposed and Infected Children and Adolescents and Their Parents One Year After SARS-CoV-2 Infection

Author

Haddad, Anneke, primary, Janda, Aleš, additional, Renk, Hanna, additional, Stich, Maximilian, additional, Frieh, Pauline, additional, Kaier, Klaus, additional, Lohrmann, Florens, additional, Nieters, Alexandra, additional, Willems, Anna, additional, Huzly, Daniela, additional, Dulovic, Alex, additional, Schneiderhan-Marra, Nicole, additional, Jacobsen, Eva-Maria, additional, Fabricius, Dorit, additional, Zernickel, Maria, additional, Stamminger, Thomas, additional, Bode, Sebastian, additional, Himpel, Theda, additional, Remppis, Jonathan, additional, Engel, Corinna, additional, Peter, Andreas, additional, Ganzenmueller, Tina, additional, Hoffmann, Georg Friedrich, additional, Haase, Bettina, additional, Kräusslich, Hans-Georg, additional, Müller, Barbara, additional, Franz, Axel, additional, Debatin, Klaus-Michael, additional, Henneke, Philipp, additional, Toenshoff, Burkhard, additional, and Elling, Roland, additional

Published
2022
Full Text
View/download PDF

17. Typically asymptomatic but with robust antibody formation: Children’s unique humoral immune response to SARS-CoV-2

Author

Renk, Hanna, primary, Dulovic, Alex, additional, Becker, Matthias, additional, Fabricius, Dorit, additional, Zernickel, Maria, additional, Junker, Daniel, additional, Seidel, Alina, additional, Groß, Rüdiger, additional, Hilger, Alexander, additional, Bode, Sebastian, additional, Fritsch, Linus, additional, Frieh, Pauline, additional, Haddad, Anneke, additional, Görne, Tessa, additional, Remppis, Jonathan, additional, Ganzemueller, Tina, additional, Dietz, Andrea, additional, Huzly, Daniela, additional, Hengel, Hartmut, additional, Kaier, Klaus, additional, Weber, Susanne, additional, Jacobsen, Eva-Maria, additional, Kaiser, Philipp D., additional, Traenkle, Bjoern, additional, Rothbauer, Ulrich, additional, Stich, Maximilian, additional, Tönshoff, Burkhard, additional, Hoffmann, Georg F., additional, Müller, Barbara, additional, Ludwig, Carolin, additional, Jahrsdörfer, Bernd, additional, Schrezenmeier, Hubert, additional, Peter, Andreas, additional, Hörber, Sebastian, additional, Iftner, Thomas, additional, Münch, Jan, additional, Stamminger, Thomas, additional, Groß, Hans-Jürgen, additional, Wolkewitz, Martin, additional, Engel, Corinna, additional, Rizzi, Marta, additional, Henneke, Philipp, additional, Franz, Axel R., additional, Debatin, Klaus-Michael, additional, Schneiderhan-Marra, Nicole, additional, Janda, Ales, additional, and Elling, Roland, additional

Published
2021
Full Text
View/download PDF

18. Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany

Author

Tönshoff, Burkhard, primary, Müller, Barbara, additional, Elling, Roland, additional, Renk, Hanna, additional, Meissner, Peter, additional, Hengel, Hartmut, additional, Garbade, Sven F., additional, Kieser, Meinhard, additional, Jeltsch, Kathrin, additional, Grulich-Henn, Jürgen, additional, Euler, Julia, additional, Stich, Maximilian, additional, Chobanyan-Jürgens, Kristine, additional, Zernickel, Maria, additional, Janda, Aleš, additional, Wölfle, Lena, additional, Stamminger, Thomas, additional, Iftner, Thomas, additional, Ganzenmueller, Tina, additional, Schmitt, Christian, additional, Görne, Tessa, additional, Laketa, Vibor, additional, Olberg, Sylvia, additional, Plaszczyca, Anna, additional, Cortese, Mirko, additional, Bartenschlager, Ralf, additional, Pape, Constantin, additional, Remme, Roman, additional, Huzly, Daniela, additional, Panning, Marcus, additional, Weigang, Sebastian, additional, Giese, Sebastian, additional, Ciminski, Kevin, additional, Ankerhold, Jakob, additional, Kochs, Georg, additional, Schwemmle, Martin, additional, Handgretinger, Rupert, additional, Niemeyer, Charlotte M., additional, Engel, Corinna, additional, Kern, Winfried V., additional, Hoffmann, Georg Friedrich, additional, Franz, Axel R., additional, Henneke, Philipp, additional, Debatin, Klaus-Michael, additional, and Kräusslich, Hans-Georg, additional

Published
2021
Full Text
View/download PDF

19. Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany

Author

Toenshoff, Burkhard, primary, Müller, Barbara, additional, Elling, Roland, additional, Renk, Hanna, additional, Meissner, Peter, additional, Hengel, Hartmut, additional, Garbade, Sven F., additional, Kieser, Meinhard, additional, Jeltsch, Kathrin, additional, Grulich-Henn, Jürgen, additional, Euler, Julia, additional, Stich, Maximilian, additional, Chobanyan-Jürgens, Kristine, additional, Zernickel, Maria, additional, Janda, Aleš, additional, Wölfe, Lena, additional, Stamminger, Thomas, additional, Iftner, Thomas, additional, Ganzenmueller, Tina, additional, Görne, Tessa, additional, Laketa, Vibor, additional, Olberg, Sylvia, additional, Plasczyczca, Anna, additional, Cortese, Mirko, additional, Pape, Constantin, additional, Remme, Roman, additional, Huzly, Daniela, additional, Panning, Marcus, additional, Weigang, Sebastian, additional, Giese, Sebastian, additional, Ciminski, Kevin, additional, Ankerhold, Jakob, additional, Kochs, Georg, additional, Schwemmle, Martin, additional, Handgretinger, Rupert, additional, Niemeyer, Charlotte M., additional, Engel, Corinna, additional, Kern, Winfried V., additional, Hoffmann, Georg Friedrich, additional, Franz, Axel, additional, Henneke, Philipp, additional, Debatin, Klaus-Michael, additional, and Kräusslich, Hans-Georg, additional

Published
2020
Full Text
View/download PDF

20. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Author

Varma, Ankur, primary, Biritxinaga, Laura, additional, Saliba, Rima M., additional, Stich, Maximilian, additional, Jauch, Sarah Francesca, additional, Afrough, Aimaz, additional, Honhar, Medhavi, additional, Popat, Uday R., additional, Shafi, Mehnaz A., additional, Shah, Nina, additional, Bashir, Qaiser, additional, Dinh, Yvonne, additional, Hosing, Chitra, additional, Champlin, Richard E., additional, and Qazilbash, Muzaffar H., additional

Published
2017
Full Text
View/download PDF

22. Humoral immune response and live-virus neutralization of the SARS-CoV-2 omicron (BA.1) variant after COVID-19 mRNA vaccination in children and young adults with chronic kidney disease

Author

Stich, Maximilian, Di Cristanziano, Veronica, Toenshoff, Burkhard, Weber, Lutz Thorsten, Doetsch, Jorg, Rammer, Marian Theodor, Rieger, Susanne, Heger, Eva, Garbade, Sven F., Burgmaier, Kathrin, Benning, Louise, Speer, Claudius, Habbig, Sandra, Haumann, Sophie, Stich, Maximilian, Di Cristanziano, Veronica, Toenshoff, Burkhard, Weber, Lutz Thorsten, Doetsch, Jorg, Rammer, Marian Theodor, Rieger, Susanne, Heger, Eva, Garbade, Sven F., Burgmaier, Kathrin, Benning, Louise, Speer, Claudius, Habbig, Sandra, and Haumann, Sophie

Abstract

Background Data on humoral immune response to standard COVID-19 vaccination are scarce in adolescent patients and lacking for children below 12 years of age with chronic kidney disease including kidney transplant recipients. Methods We therefore investigated in this retrospective two-center study (DRKS00024668; registered 23.03.2021) the humoral immune response to a standard two-dose mRNA vaccine regimen in 123 CKD patients aged 5-30 years. A live-virus assay was used to assess the serum neutralizing activity against the SARS-CoV-2 omicron (BA.1) variant. Results Children aged 5-11 years had a comparable rate and degree of immune response to adolescents despite lower vaccine doses (10 mu g vs. 30 mu g BNT162b2). Treatment with two (odds ratio 9.24) or three or more (odds ratio 17.07) immunosuppressants was an independent risk factor for nonresponse. The immune response differed significantly among three patient cohorts: 48 of 77 (62.3%) kidney transplant recipients, 21 of 26 (80.8%) patients on immunosuppressive therapy, and 19 of 20 (95.0%) patients with chronic kidney disease without immunosuppressive therapy responded. In the kidney transplant recipients, immunosuppressive regimens comprising mycophenolate mofetil, an eGFR of< 60 mL/min/1.73 m(2), and female sex were independent risk factors for nonresponse. Two of 18 (11.1%) and 8 of 16 (50.0%) patients with an anti-S1-RBD IgG of 100-1411 and > 1411 BAU/mL, respectively, showed a neutralization activity against the omicron variant. Conclusion A standard mRNA vaccine regimen in immunosuppressed children and adolescents with kidney disease elicits an attenuated humoral immune response with effective live virus neutralization against the omicron variant in approximately 10% of the patients, underlying the need for omicron-adapted vaccination.

23. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients

Author

Louise Benning, Christian Morath, Marie Bartenschlager, Heeyoung Kim, Marvin Reineke, Jörg Beimler, Mirabel Buylaert, Christian Nusshag, Florian Kälble, Paula Reichel, Maximilian Töllner, Matthias Schaier, Katrin Klein, Vladimir Benes, Tobias Rausch, Susanne Rieger, Maximilian Stich, Burkhard Tönshoff, Niklas Weidner, Paul Schnitzler, Martin Zeier, Caner Süsal, Thuong Hien Tran, Ralf Bartenschlager, Claudius Speer, Süsal, Caner (ORCID 0000-0003-2521-8201 & YÖK ID 351800), Benning, Louise, Morath, Christian, Bartenschlager, Marie, Kim, Heeyoung, Reineke, Marvin, Beimler, Jorg, Buylaert, Mirabel, Nusshag, Christian, Kaelble, Florian, Reichel, Paula, Toellner, Maximilian, Schaier, Matthias, Klein, Katrin, Benes, Vladimir, Rausch, Tobias, Rieger, Susanne, Stich, Maximilian, Toenshoff, Burkhard, Weidner, Niklas, Schnitzler, Paul, Zeier, Martin, Tran, Thuong Hien, Bartenschlager, Ralf, Speer, Claudius, Koç University Hospital, and School of Medicine

Subjects
Vaccines, Synthetic, Transplantation, COVID-19 Vaccines, SARS-CoV-2, Clinical decision-making, Clinical research, Immune modulation, Immunosuppression, Kidney transplantation, Nephrology, Practice, Solid organ transplantation, Vaccine, COVID-19, Antibodies, Viral, Antibodies, Neutralizing, Kidney Transplantation, Surgery, Transplant Recipients, Viral Envelope Proteins, Immunoglobulin G, Humans, Immunology and Allergy, Pharmacology (medical), RNA, Messenger, mRNA Vaccines
Abstract

Seroconversion after COVID-19 vaccination is impaired in kidney transplant recipients. Emerging variants of concern such as the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants pose an increasing threat to these patients. In this observational cohort study, we measured anti-S1 IgG, surrogate neutralizing, and anti-receptor-binding domain antibodies three weeks after a third mRNA vaccine dose in 49 kidney transplant recipients and compared results to 25 age-matched healthy controls. In addition, vaccine-induced neutralization of SARS-CoV-2 wild-type, the B.1.617.2 (delta), and the B.1.1.529 (omicron) variants was assessed using a live-virus assay. After a third vaccine dose, anti-S1 IgG, surrogate neutralizing, and anti-receptor-binding domain antibodies were significantly lower in kidney transplant recipients compared to healthy controls. Only 29/49 (59%) sera of kidney transplant recipients contained neutralizing antibodies against the SARS-CoV-2 wild-type or the B.1.617.2 (delta) variant and neutralization titers were significantly reduced compared to healthy controls (p < 0.001). Vaccine-induced cross-neutralization of the B.1.1.529 (omicron) variants was detectable in 15/35 (43%) kidney transplant recipients with seropositivity for anti-S1 IgG, surrogate neutralizing, and/or anti-RBD antibodies. Neutralization of the B.1.1.529 (omicron) variants was significantly reduced compared to neutralization of SARS-CoV-2 wild-type or the B.1.617.2 (delta) variant for both, kidney transplant recipients and healthy controls (p < .001 for all)., Dietmar Hopp Stiftung; Heidelberg Faculty of Medicine Rahel Goitein-Straus Program; Heidelberg Faculty of Medicine Physician Scientist Program; German Federal Research Network Applied Surveillance and Testing (BFAST); Network University Medicine; Helmholtz Association Initiative and Networking Fund Project Virological and Immunological Determinants of COVID-19 Pathogenesis

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results